Cavazzoni and colleagues also reported in cancers of unknown primary with FGFR2 amplification that the combination of infigratinib and trametinib was synergistic and reduced the activity of both the AKT/mTOR/p70S6K and the MAPK pathway beyond the effects of the monotherapies [52]. This evidence concerns the gene FGFR2 and cancer.